• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?

by April 22, 2025
by April 22, 2025

Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. 

Lilly’s orforglipron demonstrated “statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines” in the late-stage clinical trial. 

Investors bailed on Novo Nordisk shares in response as Lilly’s update stretches its lead in the anti-obesity market that many believe could be worth $100 billion over the next few years. 

NVO is now down nearly 35% versus its year-to-date high in early March. 

Novo Nordisk stock may be fairly valued at $64

Eli Lilly’s orforglipron news also made BMO analysts downgrade NVO stock to “market perform” last week. 

The investment firm slashed its price target on Novo Nordisk shares from $105 to $64 only that no longer translates to a meaningful upside from current levels. 

According to BMO analysts, “key updates from Lilly’s oral GLP-1 are likely to pressure shares, only to be compounded by what we believe to be a softer 1Q.” 

Note that Eli Lilly stock has already outperformed Novo Nordisk by a mile over the past 12 months. LLY is currently down just 13% versus its 52-week high while NVO has lost more than 70% since July of 2024. 

NVO topped Street estimates in its fiscal Q4

BMO turned more dovish on the Danish drugmaker last week as “obesity competitor Lilly has made sizable advancements in its commercial and clinical portfolio, causing it to overtake Novo’s early lead.”

NVO shares have failed to impress in recent months even though its net profit came in well above expectations in its latest reported quarter. 

In February, the pharmaceutical giant said its net profit increased by 29% on a year-over-year basis to $3.98 billion in Q4. 

Concerns that it’s losing to Eli Lilly & Co in the weight-loss market have kept investors on the sidelines despite a healthy dividend yield of 2.86% that’s tied to Novo Nordisk at writing. 

Should you invest in NVO shares today?

Lilly’s orforglipron news is significant for Novo Nordisk as its weight-loss drug, Wegovy, has been generating much of the strength in its financials. 

In its fiscal fourth quarter, the European behemoth saw its Wegovy sales more than double to $2.76 billion.

Analysts, however, had called for north of $3.0 billion instead. 

At the time, Lars Fruergaard Jørgensen, the chief executive of NVO said in a CNBC interview that “we can compete in the US market with tablet-based treatment before Lilly can launch. 

Investors should also note that BMO has a bit of a contrarian view on the pharma stock.

The consensus rating on NVO still sits at “overweight” with the mean target of $108 indicating potential upside of some 80% from current levels. 

The post Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Pharma giant Roche pledges $50 billion US investment in R&D, manufacturing
next post
Sensex, Nifty see choppy start as global jitters over Fed independence surface

Related Posts

Citi downgrades CEG stock despite Constellation Energy’s big...

June 5, 2025

Asian markets open: Kospi +1.72%, Nikkei -0.12% on...

June 5, 2025

SPYI ETF: Is this 12% yielding JEPI rival...

June 5, 2025

Citigroup to cut 3,500 technology jobs in China...

June 5, 2025

EU watchdog accuses Shein of ‘dark’ practices to...

June 5, 2025

European markets open: Stoxx 600 gains ahead of...

June 5, 2025

Laopu Gold’s HK$1,000 share price tests rally as...

June 5, 2025

India’s energy transition accelerates as coal declines and...

June 5, 2025

Top 2 reasons why the Wise share price...

June 5, 2025

CoreWeave stock is firing on all cylinders: get...

June 4, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • Can Florida Eliminate Property Taxes?

    June 5, 2025
  • The Spiritual Battle Between Communism and Capitalism

    June 5, 2025
  • Citi downgrades CEG stock despite Constellation Energy’s big deal with Meta

    June 5, 2025
  • Asian markets open: Kospi +1.72%, Nikkei -0.12% on US data; Sensex flat pre-RBI policy

    June 5, 2025
  • SPYI ETF: Is this 12% yielding JEPI rival a good fund to buy?

    June 5, 2025
  • Citigroup to cut 3,500 technology jobs in China as part of global revamp

    June 5, 2025

Editors’ Picks

  • 1

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 2

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025
  • 6

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 7

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025

Categories

  • Economy (1,357)
  • Editor's Pick (142)
  • Investing (165)
  • Stock (873)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Adobe stock price is cheap: is it...

June 1, 2025

Is the Google stock at risk as...

April 16, 2025

US picks Palantir as data analysis partner,...

May 31, 2025